13 reports of this reaction
2.0% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE reports
#7 most reported adverse reaction
HEADACHE is the #7 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Foundation Consumer Brands. There are 13 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE to HEADACHE. This represents approximately 2.0% of all 662 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 13 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.0% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, making it a notable side effect.
If you experience headache while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.